Clinical Trial Update: Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) [Phase 1]

View source ↗

Summary

Phase I imaging trial evaluating dalotuzumab in combination with erlotinib for non-small cell lung cancer; the MK-0646-008 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-small Cell Lung | Phase 1 | Status: COMPLETED